SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

MannKind Corporation (NASDAQ:MNKD) has recently released its third quarter earnings report.

“We began distributing MannKind branded Afrezza products to wholesalers during the week of July 25, 2016,” emphasized the company about the third quarter.

Q3 Financial Results

MannKind had a total revenue of $162.35 million, including a collaboration revenue of $161.78 million and commercial products revenue of $0.57 million.

The company had incurred a total of $44.13 million in total costs, up year-over-year from $26 million. This includes collaboration product costs of $22.74 million; selling, general, and administrative (SG&A) costs of $13.14 million, up year-over-year from $11.55 million; cost of goods sold of $4.33 million, down year-over-year from $8.12 million; and research and development (R&D) costs of $3.92 million, down year-over-year from $6.34 million. Consequently, operating income had come in at $118.23 million, which is comparable to an operating loss of $26 million recorded during the same period in 2015.

MannKind had a net income of $126.52 million, which is comparable to a net loss of $31.86 million recorded during the same period last year. Consequently, basic and diluted earnings per share (EPS) had come in at $0.26, which is comparable to the $(0.08) recorded during the same period last year.

Year-to-Date (YTD) Financial Results

YTD, the company has a total revenue of $162.35 million, including a collaboration revenue of $161.78 million and commercial products revenue of $0.57 million.

MannKind has incurred a total of $83.26 million in total costs, up year-over-year from $71.79 million. This includes SG&A costs of $31.60 million, down year-over-year from $32.65 million; collaboration product costs of $22.74 million; cost of goods sold of $15.57 million, down year-over-year from $15.69 million; and R&D costs of $13.36 million, down year-over-year from $23.46 million. Consequently, it has an operating income of $79.09 million, which is comparable to an operating loss of $71.79 million recorded during the same period in 2015.

MannKind has a net income of $71.69 million, which is comparable to a net loss of $91.43 million recorded during the same period last year. This means that basic and diluted EPS YTD stands at $0.16.

MannKind has closed at $0.65 on Friday.

SHARE
Previous articleIs It The Time To Invest In DHT Holdings Inc (NYSE:DHT)?
Next articleInterpace Diagnostics Group Inc (NASDAQ:IDXG) Thyramir Test Now Embraced By The Aetna Healthcare
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg, Equities.com, Hacked.com, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.